Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase

被引:35
作者
Rafati, S [1 ]
Baba, AA [1 ]
Bakhshayesh, M [1 ]
Vafa, M [1 ]
机构
[1] Pasteur Inst Iran, Dept Immunol, Tehran, Iran
关键词
Leishmania; major; amastigote-specific cysteine proteinase; vaccination;
D O I
10.1046/j.1365-2249.2000.01160.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cellular immune mechanisms resulting in interferon-gamma (IFN-gamma) production are essential for protection against cutaneous leishmaniasis. Antigens of the intracellular amastigote form of the parasite, found in mammalian hosts, are likely to be good candidates for the induction of T cell response and protection from development of leishmaniasis. We purified a stage-specific antigen from amastigote soluble antigen (A-SLA) of Leishmania major by immunoaffinity chromatography. The purified protein was characterized as a cysteine proteinase with enzymatic activity which is inhibited by E-64, and it was named the amastigote cysteine proteinase (ACP). BALB/c mice were immunized by two intraperitoneal injections, at a month interval, of 5 mu g of ACP or A-SLA in Freund's complete adjuvant (FCA). Animals were challenged 4 weeks later with 10(6) L. major promastigotes and examined 4 months after the last injection. The immunized animals developed significantly smaller or no lesions compared with controls. Spleen cells from immunized mice showed a significant proliferative response and produced a high level of IFN-gamma in response to ACP, suggesting the induction of Th1 cells after immunization. These results make 24-kD ACP a possible component for an eventual cocktail vaccine against L. major infection.
引用
收藏
页码:134 / 138
页数:5
相关论文
共 28 条
[1]  
Alexander J, 1998, J IMMUNOL, V161, P6794
[2]   THE DEVELOPMENTAL BIOLOGY OF LEISHMANIA PROMASTIGOTES [J].
BATES, PA .
EXPERIMENTAL PARASITOLOGY, 1994, 79 (02) :215-218
[3]   Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (04) :684-703
[4]  
CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435
[5]  
FRUTH U, 1993, J IMMUNOL, V150, P1857
[6]   LEISHMANIA-MAJOR AND LEISHMANIA-DONOVANI - A METHOD FOR RAPID PURIFICATION OF AMASTIGOTES [J].
GLASER, TA ;
WELLS, SJ ;
SPITHILL, TW ;
PETTITT, JM ;
HUMPHRIS, DC ;
MUKKADA, AJ .
EXPERIMENTAL PARASITOLOGY, 1990, 71 (03) :343-345
[7]   Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major [J].
Gurunathan, S ;
Sacks, DL ;
Brown, DR ;
Reiner, SL ;
Charest, H ;
Glaichenhaus, N ;
Seder, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1137-1147
[8]   EFFECTOR FUNCTIONS OF ACTIVATED MACROPHAGES AGAINST PARASITES [J].
JAMES, SL ;
NACY, C .
CURRENT OPINION IN IMMUNOLOGY, 1993, 5 (04) :518-523
[9]   IDENTIFICATION OF A MACROPHAGE-BINDING DETERMINANT ON LIPOPHOSPHOGLYCAN FROM LEISHMANIA-MAJOR PROMASTIGOTES [J].
KELLEHER, M ;
BACIC, A ;
HANDMAN, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (01) :6-10
[10]   RECOMBINANT VACCINIA VIRUSES EXPRESSING GP46 M-2 PROTECT AGAINST LEISHMANIA INFECTION [J].
MCMAHONPRATT, D ;
RODRIGUEZ, D ;
RODRIGUEZ, JR ;
YA, Z ;
MANSON, K ;
BERGMAN, C ;
RIVAS, L ;
RODRIGUEZ, JF ;
LOHMAN, KL ;
RUDDLE, NH ;
ESTEBAN, M .
INFECTION AND IMMUNITY, 1993, 61 (08) :3351-3359